Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : European Medicines Agency Recommends Asthma Treatment Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 01:23pm CET

By Adam Clark

AstraZeneca PLC (AZN.LN) said Friday that the European Medicines Agency has recommended the marketing authorization of its benralizumab drug for asthma treatment.

The pharmaceutical company said the recommendation is based on phase 3 clinical trial data and is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients.

The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The drug is also under regulatory review in the U.S., Japan and several other countries.

Shares are down 54 pence, or 1.1%, at 4908 pence at 1203 GMT.

Write to Adam Clark at [email protected]; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
01/17 CELLINK : establishes R&D lab in AstraZeneca's BioVentureHub
01/17 ASTRAZENECA : Moving Forward as a Heart Attack Survivor
01/17 ASTRAZENECA : FDA nod for Lynparza in third indication
01/17 ASTRAZENECA : Fasenra Approved in EU for Treatment of Severe Eosinophilic Asthma
01/17 Keytruda meets OS, PFS endpoints in first-line NSCLC
01/17 CAVERION OYJ : and AstraZeneca sign a Managed Services agreement covering two ph..
01/16 3SBIO INC : China FDA Approves New Once-Weekly Bydureon to Improve Glycemic Cont..
01/15 ASTRAZENECA : BYDUREON BCise injectable medicine now available in the US for pat..
01/15 MERCK AND : AstraZeneca and Merck - U.S. FDA Approves LYNPARZA in Germline BRCA-..
01/15 ASTRAZENECA : Lynparza approved by US FDA in germline BRCA-mutated metastatic br..
More news
News from SeekingAlpha
10:34a Big Biopharma in the red in early trade
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/15 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's MS Win, Aradigm FDA Panel Woes, A..
01/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 13, 2018
01/14 WEEK IN REVIEW : Hua Medicine To Raise $200 Million Through Fundings And IPO For..
Financials ($)
Sales 2017 21 849 M
EBIT 2017 5 693 M
Net income 2017 2 297 M
Debt 2017 12 304 M
Yield 2017 3,96%
P/E ratio 2017 35,20
P/E ratio 2018 30,15
EV / Sales 2017 4,55x
EV / Sales 2018 4,54x
Capitalization 87 146 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 69,0 $
Spread / Average Target 0,01%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-2.55%88 155
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287